FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Jacques-Henri Jacob

Research Profile

Procedures

Chemicals & Drugs

Disorders

Concepts & Ideas

Co-author Network

Publications

TOP 3
Marie-Christine Etienne-Grimaldi; Roger Faroux; Jean-Louis Formento; Eric Francois; Mireille Francoual; Isabelle Hennebelle; Jacques-Henri Jacob; Jaafar Bennouna; Etienne Chatelut; Jean-Yves Douillard; Chaza El Hannani; Gérard Milano
Multifactorial pharmacogenetic analysis in colorectal cancer patients receiving 5-fluorouracil-based therapy together with cetuximab-irinotecan.
Yves Bécouarn; Pierre Senesse; S Thézenas; Eveline Boucher; Antoine Adenis; L Cany; Jacques-Henri Jacob; F Cvitkovic; C Montoto-Grillot; Marc Ychou
A randomized phase II trial evaluating safety and efficacy of an experimental chemotherapy regimen (irinotecan + oxaliplatin, IRINOX) and two standard arms (LV5 FU2 + irinotecan or LV5 FU2 + oxaliplatin) in first-line metastatic colorectal cancer: a study of the Digestive Group of the Fédération Nationale des Centres de Lutte Contre le Cancer.
Pierre Michel; Antoine Adenis; Frédéric Di Fiore; Eveline Boucher; Marie-Pierre Galais; Laetitia Dahan; Xavier Mirabel; Hadji Hamidou; Jean-Luc Raoul; Jacques-Henri Jacob; Marie-France Hellot; S Prod'homme; Bernard Paillot
Induction cisplatin-irinotecan followed by concurrent cisplatin-irinotecan and radiotherapy without surgery in oesophageal cancer: multicenter phase II FFCD trial.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Jacques-Henri Jacob (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: Marie-Christine Etienne-Grimaldi; Roger Faroux; Jean-Louis Formento; Eric Francois; Mireille Francoual; Isabelle Hennebelle; Jacques-Henri Jacob; Jaafar Bennouna; Etienne Chatelut; Jean-Yves Douillard; Chaza El Hannani; Gérard Milano
Multifactorial pharmacogenetic analysis in colorectal cancer patients receiving 5-fluorouracil-based therapy together with cetuximab-irinotecan.
British journal of clinical pharmacology 2012;73(5):776-85.
2007: Yves Bécouarn; Pierre Senesse; S Thézenas; Eveline Boucher; Antoine Adenis; L Cany; Jacques-Henri Jacob; F Cvitkovic; C Montoto-Grillot; Marc Ychou
A randomized phase II trial evaluating safety and efficacy of an experimental chemotherapy regimen (irinotecan + oxaliplatin, IRINOX) and two standard arms (LV5 FU2 + irinotecan or LV5 FU2 + oxaliplatin) in first-line metastatic colorectal cancer: a study of the Digestive Group of the Fédération Nationale des Centres de Lutte Contre le Cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2007;18(12):2000-5.
2006: Pierre Michel; Antoine Adenis; Frédéric Di Fiore; Eveline Boucher; Marie-Pierre Galais; Laetitia Dahan; Xavier Mirabel; Hadji Hamidou; Jean-Luc Raoul; Jacques-Henri Jacob; Marie-France Hellot; S Prod'homme; Bernard Paillot
Induction cisplatin-irinotecan followed by concurrent cisplatin-irinotecan and radiotherapy without surgery in oesophageal cancer: multicenter phase II FFCD trial.
British journal of cancer 2006;95(6):705-9.
2006: Frédéric Di Fiore; Stéphane Lecleire; Olivier Rigal; Marie-Pierre Galais; Emmanuel Ben Soussan; Isabelle David; Bernard Paillot; Jacques-Henri Jacob; Pierre Michel
Predictive factors of survival in patients treated with definitive chemoradiotherapy for squamous cell esophageal carcinoma.
World journal of gastroenterology : WJG 2006;12(26):4185-90.
2006: Frédéric Di Fiore; Stéphane Lecleire; Marie-Pierre Galais; Olivier Rigal; Brigitte Vié; Isabelle David; Hadji Hamidou; Bernard Paillot; Jacques-Henri Jacob; Pierre Michel
Impact of radiation schedule and chemotherapy duration in definitive chemoradiotherapy regimen for esophageal cancer.
Gastroentérologie clinique et biologique 2006;30(6-7):845-51.
2006: Jaafar Bennouna; H Perrier; Bernard Paillot; Frank Priou; Jacques-Henri Jacob; M Hebbar; S Bordenave; Jean-François Seitz; F Cvitkovic; Etienne Dorval; K Malek; D Tonelli; Jean-Yves Douillard
'A phase II study of oral uracil/ftorafur (UFT) plus leucovorin combined with oxaliplatin (TEGAFOX) as first-line treatment in patients with metastatic colorectal cancer'.
British journal of cancer 2006;94(1):69-73.
2005: Michel Ducreux; Marc Ychou; Agnès Laplanche; Erick Gamelin; Philippe Lasser; Fares Husseini; François Quenet; Frédéric Viret; Jacques-Henri Jacob; Valérie Boige; Dominique Elias; Jean-Robert Delperro; Monique Luboinski
Hepatic arterial oxaliplatin infusion plus intravenous chemotherapy in colorectal cancer with inoperable hepatic metastases: a trial of the gastrointestinal group of the Federation Nationale des Centres de Lutte Contre le Cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(22):4881-7.
2005: Thierry Conroy; Bernard Paillot; Eric François; Roland Bugat; Jacques-Henri Jacob; Ulrich Stein; Salvador Nasca; Jean-Philippe Metges; Olivier Rixe; Pierre Michel; Emmanuelle Magherini; Aliette Hua; Gael Deplanque
Irinotecan plus oxaliplatin and leucovorin-modulated fluorouracil in advanced pancreatic cancer--a Groupe Tumeurs Digestives of the Federation Nationale des Centres de Lutte Contre le Cancer study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(6):1228-36.
2002: Christophe Louvet; Thierry André; Jean-Marie Tigaud; Erick Gamelin; Jean-Yves Douillard; R Brunet; Eric François; Jacques-Henri Jacob; D Levoir; Abdelkrim Taamma; Philippe Rougier; Esteban Cvitkovic; Aimery de Gramont
Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(23):4543-8.
2002: Marc Ychou; Jean-Luc Raoul; Françoise Desseigne; C Borel; F X Caroli-Bosc; Jacques-Henri Jacob; Jean-François Seitz; Andrew Kramar; Aliette Hua; P Lefebvre; C Couteau; Yacine Merrouche
High-dose, single-agent irinotecan as first-line therapy in the treatment of metastatic colorectal cancer.
Cancer chemotherapy and pharmacology 2002;50(5):383-91.
2001: Jean-François Seitz; A Sarradet; Eric François; Jacques-Henri Jacob; J M Ollivier; Philippe Rougier; A Roussel
Carcinoma of the oesophagus.
British journal of cancer 2001;84 Suppl 2():61-4.
2001: C Delcambre; Jacques-Henri Jacob; D Pottier; M Gignoux; J M Ollivier; B Vie; A Roussel; P Segol
Localized squamous-cell cancer of the esophagus: retrospective analysis of three treatment schedules.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2001;59(2):195-201.
2001: Theo Wobbes; Benoît Baron; Bernard Paillot; Jacques-Henri Jacob; P Haegele; M Gignoux; P Michel; ML Couvreur
Prospective randomised study of split-course radiotherapy versus cisplatin plus split-course radiotherapy in inoperable squamous cell carcinoma of the oesophagus.
European journal of cancer (Oxford, England : 1990) 2001;37(4):470-7.
1997: Harry Bleiberg; Thierry Conroy; Bernard Paillot; AJ Lacave; Geert H Blijham; Jacques-Henri Jacob; Laurent Bedenne; M Namer; P De Besi; F Gay; L Collette; TM Sahmoud
Randomised phase II study of cisplatin and 5-fluorouracil (5-FU) versus cisplatin alone in advanced squamous cell oesophageal cancer.
European journal of cancer (Oxford, England : 1990) 1997;33(8):1216-20.